CINV Professional Support Resources

Professional resources

Resources from the maker of EMEND

Patient education materials

We have created a variety of materials to help your patients with their questions about chemotherapy and CINV, provide useful tracking tools to help them monitor their postchemotherapy nausea and vomiting, and understand and evaluate CINV treatment options.

Provide your patients with a symptom tracker and patient brochure. And get a copy of the Multinational Association of Supportive Care in Cancer’s MASCC Antiemesis Tool (MAT).

Access these downloadable materials today. Visit Merck Product Services.

Important Safety Information

EMEND and EMEND for Injection, in combination with other antiemetic agents, are indicated in adults for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.

EMEND and EMEND for Injection have not been studied for treatment of established nausea and vomiting. Chronic continuous administration of EMEND or EMEND for Injection is not recommended.

Selected Important Safety Information

In clinical trials of EMEND in patients receiving highly emetogenic chemotherapy, the most common adverse events reported at a frequency greater than with standard therapy, and at an incidence of 1% or greater were hiccups (4.6% EMEND vs 2.9% standard therapy), asthenia/fatigue (2.9% vs 1.6%), increased ALT (2.8% vs 1.5%), increased AST (1.1% vs 0.9%), constipation (2.2% vs 2.0%), dyspepsia (1.5% vs 0.7%), diarrhea (1.1% vs 0.9%), headache (2.2% vs 1.8%), and anorexia (2.0% vs 0.5%).

In clinical trials of EMEND in patients receiving moderately emetogenic chemotherapy, the most common adverse events reported at a frequency greater than with standard therapy were eructation (1.0% EMEND vs 0.1% standard therapy) and fatigue (1.4% vs 0.9%).

In a clinical trial evaluating safety of the 1-day regimen of EMEND for Injection 150 mg compared with the 3-day regimen of EMEND, the safety profile was generally similar to that seen in prior highly emetogenic chemotherapy studies with aprepitant. However, infusion-site reactions occurred at a higher incidence in patients who received fosaprepitant (3.0%) than in those who received aprepitant (0.5%). Those infusion-site reactions included infusion-site erythema, infusion-site pruritus, infusion-site pain, infusion-site induration, and infusion-site thrombophlebitis.

Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.